MetaCap

Abivax SA (ABVX) vs Ligand Pharmaceuticals (LGND)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ligand Pharmaceuticals (LGND) has outperformed Abivax SA (ABVX) over the past year, gaining 44.0% versus a loss of 38.5%. Abivax SA is the larger company by market cap ($6.41 billion vs $5.74 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABVX-38.55%LGND+43.98%
+67%+11%-44%
Nov 21, 20251 yearNov 20, 2026
ABVX+781.93%LGND+450.68%
+1727%+803%-120%
Oct 16, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABVX versus LGND key metrics
MetricABVXLGND
Share price$73.20$286.85
Market cap$6.41B$5.74B
1-day change-9.24%-0.03%
YTD return-45.72%+51.72%
1-year return-38.55%+43.98%
5-year return—+193.16%
P/E ratio (TTM)—115.20
Forward P/E—24.00
EPS (TTM)$-6.08$2.49
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$268.09M
Revenue growth (YoY)—+60.40%
Net income (latest FY)—$124.45M
Operating margin—15.29%
Net margin—46.42%
52-week high$148.83$326.63
52-week low$62.70$175.89
Distance from 52-week high-50.82%-12.18%
Analyst consensusnonestrong_buy
Avg. price target upside+123.47%+25.94%
Average volume1.35M230.79K
Shares outstanding87.54M20.00M
Employees9847
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LGND has outperformed ABVX by 82.5 percentage points over the past year.

About Abivax SA

ABVX stock →

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees

About Ligand Pharmaceuticals

LGND stock →

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees

ABVX vs LGND FAQ

Which is bigger, Abivax SA or Ligand Pharmaceuticals?

Abivax SA (ABVX) is larger, with a market capitalization of $6.41B compared with $5.74B for Ligand Pharmaceuticals (LGND).

Which stock has performed better over the past year, ABVX or LGND?

LGND returned +43.98% over the past 12 months, compared with -38.55% for ABVX (price return, excluding dividends). Past performance does not predict future results.

Are Abivax SA and Ligand Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons